New drug combo aims to shrink ovarian tumors in Hard-to-Treat patients
NCT ID NCT07339553
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two oral drugs, zeprumetostat and fuzuloparib, in 30 people with advanced or recurrent ovarian cancer who do not have BRCA gene mutations. The goal is to see if the combination can shrink tumors and delay progression. Participants first take fuzuloparib alone, then both drugs together until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zeprumetostat and Fuzuloparib (two oral drugs)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced or recurrent ovarian cancer who have not responded to standard therapies.
- What could go wrong
- This is an early phase 2 trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects like blood toxicity, and it is not yet known if it improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN EPITHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.